Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial

Trial Profile

Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Dasatinib (Primary) ; Carboplatin; Etoposide phosphate; Ifosfamide
  • Indications CNS cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Hepatic tumours; Lymphoma; Neuroblastoma; Osteosarcoma; Renal cancer; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 10 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 31 Dec 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top